Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepine use disorders are a common clinical problem among methadone maintenance treatment patients and have adverse effects on clinical outcomes. OBJECTIVES: To evaluate gabapentin for the outpatient treatment of benzodiazepine abuse or dependence in methadone maintenance patients. METHODS: Participants (n = 19) using benzodiazepines at least 4 days per week were enrolled into an 8-week randomized double-blind placebo-controlled outpatient pilot trial. All participants received a manual-guided supportive psychotherapy aimed to promote abstinence. Study medication was titrated over a 2-week period to a maximum dose of gabapentin 1200 mg or placebo three times a day. Benzodiazepine use was assessed using urine toxicology confirmed self-report. Benzodiazepines were not provided as part of study participation; participants were provided guidance to gradually reduce benzodiazepine intake. RESULTS: Sixteen participants had post-randomization data for analysis. Retention at week eight was 50%. The mean dose of gabapentin achieved by titration was 2666 mg/day (SD = ± 1446). There were no significant between group differences on benzodiazepine use outcomes (amount benzodiazepine per day [Mann-Whitney U = 27, p = 0.745], abstinent days per week [U = 28, p = 0.811]) and Clinical Instrument Withdrawal Assessment (CIWA)-benzodiazepines scale (U = 29.0, p = 0.913). One participant in the gabapentin group discontinued study medication because of peripheral edema. Two participants in the placebo group requested admission for inpatient detoxification treatment. CONCLUSION: In outpatient methadone-maintained patients with benzodiazepine use disorder, gabapentin did significantly decrease benzodiazepine use relative to placebo. The small sample recruited for this trial may have limited the ability to detect a group difference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Additionally, younger patients tend to have a decreased success rate of discontinuing BZD use than older patients [66].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [66]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings
Denis, C., Fatseas, M., Lavie, E., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005194.pub2 · Cited by 122 · cited 2×
“No clearly effective pharmacotherapy for the treatment of benzodiazepine use disorder has been identified (24).”
BackgroundRetractedSequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family
Schofield, P. R., Darlison, M. G., Fujita, N., Burt, D. R., Stephenson, F. A., Rodriguez, H., Rhee, L. M., Ramachandran, J., Reale, V., Glencorse, T. A., et al. (1987) · Nature · doi:10.1038/328221a0 · Cited by 1,622 · cited 1×
“Benzodiazepines bind directly to a specific modulatory site that is present on GABAA receptors (16,17), which enhances the effect of the inhibitory neurotransmitter, but does not open the chloride channel in the absence of GABA.”
BackgroundThe Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the α2δ Subunit of a Calcium Channel
Gee, N. S., Brown, J. P., Dissanayake, V. U. K., Offord, J., Thurlow, R., & Woodruff, G. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5768 · Cited by 1,181
A summary of mechanistic hypotheses of gabapentin pharmacology
Taylor, C. P., Gee, N. S., Su, T.-Z., Kocsis, J. D., Welty, D. F., Brown, J. P., Dooley, D. J., Boden, P., & Singh, L. (1998) · Epilepsy Research · doi:10.1016/s0920-1211(97)00084-3 · Cited by 774 · cited 7×
“The mechanism of these changes is unclear, and may involve alterations in the expression of individual GABAA receptor subtypes (18), but are known to be linked to the dose and duration of benzodiazepine use (19).”
BackgroundInfluentialThe mechanisms of action of gabapentin and pregabalin
SILLS, G. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.003 · Cited by 671 · cited 1×
“Gabapentin binds to the α2δ-1 and α2δ-2 subunits of voltage-gated calcium channels (44–46) and inhibits calcium currents (47–49), which leads to attenuation of postsynaptic excitability (50,51).”
BackgroundTreatment of Social Phobia With Gabapentin: A Placebo-Controlled Study
Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 395 · cited 1×
“Gabapentin has anxiolytic (61,62) and sedating”
Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340
The effect of gabapentin on brain gamma‐aminobutyric acid in patients with epilepsy
Petroff, O. A. C., Rothman, D. L., Behar, K. L., Lamoureux, D., & Mattson, R. H. (1996) · Annals of Neurology · doi:10.1002/ana.410390114 · Cited by 285 · cited 1×
“analogue of the neurotransmitter GABA (40), and while it is not a GABA-mimetic agent (41), it has been shown to increase synaptic GABA levels (42,43).”
BackgroundPlacebo-Controlled Study of Gabapentin Treatment of Panic Disorder
Pande, A. C., Pollack, M. H., Crockatt, J., Greiner, M., Chouinard, G., Lydiard, R. B., Taylor, C. B., Dager, S. R., & Shiovitz, T. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00011 · Cited by 279 · cited 1×
“Gabapentin has anxiolytic (61,62) and sedating”
Calcium Channel α2δ Subunits—Structure and Gabapentin Binding
Marais, E., Klugbauer, N., & Hofmann, F. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.5.1243 · Cited by 262
Research works printed but not linked: 13
- Bleich A, 1999, A 1 year prospective study in an Israeli clinic. Addiction, 94, 1533
- Bleich A, 2002, Isr J Psychiatry Relat Sci, 39
- Caplehorn JR, 2002, Aust N Z J Public Health, 26, 362
- Eiroa-Orosa FJ, 2010, methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend, 112, 226
- Cantopher T, 1990, A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry, 156, 406
- Hallstrom C, 1988, Postgrad Med J, 64, 40
- Lemoine P, 1997, A controlled study, hydroxyzine versus placebo]. L’Encephale, 23, 290
- Stitzer M, 1982, NIDA Res Monogr, 41, 282
- 10.1037/0022-006X.60.6.927 · DOI · Paper page
- 10.1042/bj3420313 · doi:10.1042/bj3420313 · Paper page
- Wang PW, 2002, Psychopharmacol Bull, 36, 44
- Salinsky MC, 2002, Epilepsia, 43482
- Carroll KM, 1999, West Haven, CT: Yale University Psychotherapy Development Center Training Series No, 4
Cited by
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“Additionally, younger patients tend to have a decreased success rate of discontinuing BZD use than older patients [66].”
BackgroundPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317753340 · Cited by 109
Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016
Pauly, N., Delcher, C., Slavova, S. S., Lindahl, E., Talbert, J., & Freeman, P. R. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.3.246 · Cited by 86
Metadata
- Authors
- Mariani, J. J., Malcolm, R. J., Mamczur, A. K., Choi, J. C., Brady, R., Nunes, E., & Levin, F. R.
- Affiliations
- New York State Psychiatric Institute (US)
- Medical University of South Carolina (US)
- Narco Freedom (United States) (US)
- Corresponding author
- Mariani, John J.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-03-10
- Volume
- 42
- Issue
- 3
- Pages
- 333-340
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC4968045
- OpenAlex
- W2301693649
- Cited by
- 27
- References
- 70
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 2
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-08-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (K23-DA021209, K24 029647, K24-DA022412, P50-DA09236)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- gabapentin, benzodiazepine use disorder, benzodiazepine dependence, benzodiazepine misuse, methadone maintenance treatment, opioid use disorder, outpatient care, supportive therapy, benzodiazepine withdrawal, abstinence
- MeSH terms
- Gabapentin, Adolescent, Adult, Aged, Amines, Benzodiazepines, Combined Modality Therapy, Cyclohexanecarboxylic Acids, Double-Blind Method, Female, gamma-Aminobutyric Acid, Humans, Male, Methadone, Middle Aged, Pilot Projects, Psychotherapy, Substance Withdrawal Syndrome, Substance-Related Disorders, Young Adult, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. https://app.cochat.ai/papers/10.3109/00952990.2015.1125493
- The paper
- Mariani, J. J., Malcolm, R. J., Mamczur, A. K., Choi, J. C., Brady, R., Nunes, E., & Levin, F. R. (2016). Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients. The American Journal of Drug and Alcohol Abuse. https://doi.org/10.3109/00952990.2015.1125493
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.